Our findings confirmed that hsa_circ_0002130 served as a promotion role in osimertinib-resistant NSCLC.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: